Reckitt Strengthens US and China Provide Chains Amid Rising Commerce Tensions

THE WHAT? Reckitt is ramping up native manufacturing within the US and China to scale back its reliance on imports and safeguard its provide chain towards potential commerce conflicts. Key investments embrace a US$190 million manufacturing facility in North Carolina for Mucinex manufacturing and a 300 million yuan (US$40.9 million) R&D middle in Shanghai.

THE DETAILS The North Carolina manufacturing facility, operational by 2027, will decrease US imports to 25% of Reckitt’s native gross sales by producing Mucinex tablets and liquids domestically.

In China, Reckitt is increasing its Taicang manufacturing facility to incorporate condom manufacturing beginning in 2026, and its new Shanghai R&D middle will deal with merchandise tailor-made to the native market.

Because the US considers protectionist insurance policies, with potential tariffs of as much as 60% on Chinese language imports, Reckitt’s technique goals to scale back reliance on mono-sourcing whereas enhancing manufacturing flexibility.

At the moment, 80% of Reckitt’s merchandise offered in China are already manufactured regionally, positioning the corporate nicely to fulfill shopper demand regardless of commerce uncertainties.

THE WHY? Reckitt’s proactive investments replicate a strategic pivot to fortify its provide chain in response to geopolitical challenges.